Plain-English translation of NCT06676631 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether NK010 or NK042—experimental cell therapies—can work better when combined with , a medication already used for lupus. The study is for people whose lupus or lupus kidney disease hasn't gotten better despite being on standard treatments. Researchers want to see if adding these new cell therapies can help control the disease.
Some people with lupus don't respond well to the medications currently available, and their disease keeps causing damage. This trial is exploring whether this new cell-based approach could offer hope to those patients whose lupus has been resistant to standard care.
You likely qualify if…
You likely don't qualify if…
If you join, you'll receive on day 1, followed by three infusions of the experimental cell therapy on days 4, 6, and 8. You'll then be followed closely with visits at 2 weeks, 4 weeks, 2 months, 3 months, and then every 3 months for a full year. Throughout this time, researchers will monitor how your lupus responds to the new treatment through blood tests, kidney function tests, and clinical assessments.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
China